Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 13, 2020 06:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Expands its Compassionate Use Program: Treated First COVID-19 Patient in U.S. Under FDA Single Patient Expanded Access Program

Cleared by FDA to proceed with the treatment in U.S. under Coronavirus Treatment Acceleration Program (CTAP)Pluristem’s main focus: multinational clinical trial of PLX cells for treatment of...
April 07, 2020 07:50 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Reports Preliminary Data from its COVID-19 Compassionate Use Program, Treating Seven Patients with Acute Respiratory Failure

All treated patients were in Intensive Care Units (ICU) on ventilators and suffered from Acute Respiratory Distress Syndrome (ARDS)100% survival rate for all seven patients6 patients completed 1 week...
March 30, 2020 07:30 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Treated First Three COVID-19 Patients in Israel under Compassionate Use

Expects to treat more patients in Israel in the coming daysCompany is in discussions with regulators in the U.S. and Europe to define its clinical strategy for COVID-19 HAIFA, Israel, March 30, 2020...
March 26, 2020 08:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Provides Update on COVID-19: Preparedness, Current Phase III Clinical Trials Status and Treatment Development Activity

HAIFA, Israel, March 26, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
March 17, 2020 08:30 ET | Source: Pluristem Therapeutics, Inc.

Israeli Ministry of Health Clears a Path to Allow Per Patient Compassionate Use Treatment of Covid-19 Patients with Pluristem’s PLX Cells

HAIFA, Israel, March 17, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
March 12, 2020 09:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem and Charité University of Medicine Berlin Join Forces Targeting Potential Treatment for Respiratory and Inflammatory Intratissue Complications Caused by COVID-19

HAIFA, Israel, March 12, 2020 (GLOBE NEWSWIRE) -- HAIFA, Israel, March 12, 2020 - Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform...
March 03, 2020 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Receives Response from U.S. BARDA for Acute Radiation Syndrome Research Proposal

HAIFA, Israel, March 03, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
February 10, 2020 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Therapeutics CEO Issues Shareholder Update

HAIFA, Israel, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel cell therapy products,...
February 03, 2020 07:00 ET | Source: Pluristem Therapeutics, Inc.

In Its Path Towards Marketing, Pluristem Provides Highly Favorable Market Access Data Regarding the Critical Limb Ischemia Market in U.S.

HAIFA, Israel, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
December 17, 2019 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Completes 75% Enrollment in its Pivotal Phase III CLI Clinical Study

HAIFA, Israel, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...